Skip to main content

Table 1 Patient demographics and symptoms at initial diagnosis

From: Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study

  SACQ (170) SQCQ (187) p
Age at diagnosis (years) 32.09 ± 14.35 38.61 ± 15.08 < 0.001
Gender (male: female) 21:149 19:168 0.512
Time to get SACQ/SQCQ (months) 22.55 (12.70, 50.36) 18.07 (10.47, 36.53) 0.036
Follow-up time (months) 50.43 (32.93, 82.69) 53.17 (30.40, 80.73) 0.706
The SACQ/SQCQ period (months) 20.30 (10.64, 33.49) 24.00 (12.00, 43.30) 0.028
Dose of antimalarials at the start of SACQ/SQCQ (g) 0.20 (0.20, 0.40) 0.20 (0.20, 0.40) 0.058
Taking immunosuppressants at the start of SACQ/SQCQ (%) 96/170 (56.5%) 99/187 (52.9) 0.504
LN 62 (36.5%) 68 (36.4%) 0.983
NPSLE 8 (4.7%) 11 (5.9%) 0.621
Thrombocytopenia 23/170 (13.5%) 36/187 (19.3%) 0.146
Hemolytic anemia 14/170 (8.2%) 14/187 (7.5%) 0.793
Pulmonary hypertension 4/170 (2.4%) 5/187 (2.7%) 1.000
Myocardial involvement 0/170 (0) 3/187 (1.6%) 0.281
ILD 3/170 (1.8%) 6/187 (3.2%) 0.595
Alveolar hemorrhage 0/170 (0) 0/187 (0) NA
Smooth muscle involvement 6/170 (3.5%) 5/187 (2.7%) 0.640
Polyserositis 8/170 (4.7%) 8/187 (4.3%) 0.845
APS 7/170 (4.1%) 5/187 (2.7%) 0.450
TTP or TMA 0/170 (0) 0/187 (0) NA
Secondary SS 19/170 (11.2%) 25/187 (13.4%) 0.529
  1. SACQ serologically active clinically quiescent, SQCQ serologically quiescent clinically quiescent, SACA serologically active clinically active, NA not applicable, LN lupus nephritis, NPSLE neuropsychiatric SLE, ILD interstitial lung disease, APS antiphospholipid antibody syndrome, TTP thrombotic thrombocytopenic purpura, TMA thrombotic microangiopathy, SS Sjogren syndrome